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Abstract
Background: Uncontrolled active rheumatoid arthritis can lead to increasing disability and reduced quality of life
over time. ‘Treating to target’ has been shown to be effective in active established disease and also in early disease.
However, there is a lack of nationally agreed treatment protocols for patients with established rheumatoid arthritis
who have intermediate disease activity. This trial is designed to investigate whether intensive management of disease
leads to a greater number of remissions at 12 months. Levels of disability and quality of life, and acceptability
and cost-effectiveness of the intervention will also be examined.
Methods: The trial is a 12-month, pragmatic, randomised, open-label, two-arm, parallel-group, multicentre trial
undertaken at specialist rheumatology centres across England. Three hundred and ninety-eight patients with
established rheumatoid arthritis will be recruited. They will currently have intermediate disease activity (disease
activity score for 28 joints assessed using an erythrocyte sedimentation rate of 3.2 to 5.1 with at least three
active joints) and will be taking at least one disease-modifying anti-rheumatic drug.
Participants will be randomly selected to receive intensive management or standard care. Intensive management will
involve monthly clinical reviews with a specialist health practitioner, where drug treatment will be optimised and an
individualised treatment support programme delivered based on several principles of motivational interviewing to address
identified problem areas, such as pain, fatigue and adherence. Standard care will follow standard local pathways and will be
in line with current English guidelines from the National Institute for Health and Clinical Excellence. Patients will be assessed
initially and at 6 and 12 months through self-completed questionnaires and clinical evaluation.
Discussion: The trial will establish whether the known benefits of intensive treatment strategies in active rheumatoid
arthritis are also seen in patients with established rheumatoid arthritis who have moderately active disease. It will evaluate
both the clinical and cost-effectiveness of intensive treatment.
Trial registration: Current Controlled Trials, ID: ISRCTN70160382. Registered on 16 January 2014.
Keywords: Rheumatoid arthritis, Intermediate disease activity, Treating to target, Intensive treatment, Randomised controlled
trial, Tumour necrosis factor inhibitors
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Background
Rheumatoid arthritis (RA) is an immunologically driven,
progressive, long-term condition. It is characterised by
persistent synovitis, systemic inflammation and detect-
able autoantibodies, including rheumatoid factor and
anti-cyclic citrullinated peptide antibody [1]. Ongoing
joint inflammation damages cartilage, bone and tendons;
systemic inflammation causes extra-articular complica-
tions like vasculitis and lung disease. Uncontrolled active
RA leads to disability, decreased quality of life (QoL)
and increased co-morbidity. The end result is loss of
work, major medical and social costs and high morbidity
and mortality [2, 3].
RA management involves a multidisciplinary team in-
cluding rheumatologists, specialist nurses, therapists and
others. The team provide education, particularly on self-
management, medication, psychological support, exer-
cise and joint protection [4]. RA outcomes are optimised
by treating patients to pre-defined targets [5–7]; the
most appropriate target is remission.
Drug treatment focusses on controlling joint inflam-
mation with disease-modifying anti-rheumatic drugs
(DMARDs). They reduce synovitis, systemic inflamma-
tion and disability. The dominant DMARD is metho-
trexate; others include sulfasalazine and leflunomide [8].
The impact of DMARDs can be maximised by using
them in combination. However, side effects limit
DMARD use by both clinicians and patients [4]. Steroids
(glucocorticoids) also reduce joint inflammation [9]. In
the short-term steroids can be combined with DMARDs
to reduce erosions and to treat systemic disease. Long-
term steroid use has unacceptable toxicity [10].
Biological agents, given when DMARDs cannot con-
trol RA, have revolutionised its management. Biologics
such as tumour necrosis factor inhibitors (TNFi), rituxi-
mab, abatacept and tocilizumab are highly effective [11].
They are mainly given with methotrexate to increase ef-
ficacy and reduce blocking antibodies [12]. Their main
risk is infection [13] and use is limited by their high
costs [14]. Although they substantially improve RA out-
come, they do not cure the disease.
RA patients are distinguished into categories according
to their disease activity levels. This is currently undertaken
on the basis of the Disease Activity Score for 28 joints
(DAS28), which is a composite measure including assess-
ment of tender and swollen joint (based on 28 joints), the
erythrocyte sedimentation rate (ESR) and patient global as-
sessments on a 100-mm Visual Analogue Scale (VAS) [15].
DAS28 scores divide patients with established RA into
four categories. These are as follows:
1. High disease activity (DAS28 over 5.1)
2. Intermediate (or moderate) disease activity (DAS28 over
3.2 to 5.1)
3. Low disease activity (DAS28 2.6 to 3.2)
4. Remission (DAS28 under 2.6)
Randomised clinical trials (RCTs) enrol patients with
RA who have high disease activity. There is strong evi-
dence from RCTs that patients with RA with high dis-
ease activity benefit from treatment with DMARDs and
biologics. Remission or low disease activity are the goals
of treatment. This approach, termed ‘treat to target’ [16],
is supported by a strong evidence base [17, 18]. When
patients achieve sustained low disease activity or remis-
sion, most clinicians either maintain treatment or reduce
treatment levels. However, many RA patients currently
attending rheumatology clinics have intermediate (or
moderate) disease activity levels [19]. There is only lim-
ited evidence that intensive treatment strategies benefit
such patients and there is uncertainty about how best to
treat them. One key reason for these doubts is that such
patients are not usually included within RCTs [19–22].
There are a number of clinical guidelines that sum-
marise how best to manage patients with RA [23–25].
Those by the National Institute for Health and Clinical
Excellence (NICE) are the most relevant for clinical
practice in England [25]. They make some general
recommendations on the current management of pa-
tients with intermediate disease, which can be sum-
marised as follows:
 Maintain suppressive treatment with DMARDs and
steroids
 Maintain symptomatic therapy (analgesics/non-steroidal
anti-inflammatory drugs)
 Carry out annual specialist reviews, with urgent
specialist reviews and treatment modification for flares
(DAS28 over 5.1) or clinically significant adverse events
There has been discussion about the relative merits of
giving treatments, such as biologics, to patients with
intermediate disease activity, but no nationally agreed
protocols exist in England. There is substantial inter-
national variation on the use of biological treatments
and in some European countries and in North America,
patients with intermediate disease activity are often pre-
scribed biological treatment. The absence of any agreed
treatment protocols for patients with intermediate dis-
ease activity is a major challenge in defining the most
appropriate way to treat many RA patients attending
specialist clinics in England [25].
A number of strategy trials have shown the benefits of
combining treatments – DMARDs, steroids and, in some
trials, biologics – to optimise outcomes, and have con-
firmed the benefit of treating to target, where patients are
treated until they reach the therapeutic target of remission
or low disease activity [16]. ‘Intensive management’ (IM)
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approaches used in these strategy trials give the best out-
comes for RA so far reported [17, 18].
A characteristic feature of RA trials is their focus on in-
creasing treatment in patients with high disease activity.
One reason is that such patients have pressing needs to
justify treatment change. A second is the relative ease of
showing treatment benefit in patients with high disease
activity. As a consequence, trials rarely enrol patients with
intermediate disease activity [19–22]. A common feature
of patients with intermediate disease is the duration of
their RA and multiple historical treatment changes that
have often been made to achieve acceptable levels of dis-
ease activity for the patient. Recruiting intermediate pa-
tients to a medication optimisation trial would require
additional support components that would result in pa-
tients taking medications that they may have perceived to
have been previously unsuccessful. Therefore, optimising
treatment in intermediate disease requires components
that would address knowledge, motivation and shared
decision-making [26].
Medication can alleviate symptoms and halt disease pro-
gression in rheumatoid arthritis (RA). Nevertheless, medi-
cation non-adherence is common in RA and poses a
significant barrier to improving clinical outcomes in RA
with only 58–82% of RA patients adhering to DMARDs
[27]. Factors that can influence adherence include pa-
tients’ negative beliefs about medicines and their condi-
tion, as well as their degree of satisfaction with
information about DMARDs [28, 29]. Similarly, adherence
to biologic treatments, such as adalimumab, is driven by
psychological factors, particularly medication beliefs [30].
In addition to the impact that RA has on joints and
physical disability, it also significantly affects QoL [31].
Fatigue is reported in over 80% of RA patients [32–34]
and 57% of RA patients identify fatigue as the most
problematic symptom of their condition [35]. Disease
activity might not be the sole factor exerting a significant
impact on fatigue; it may also result from a constellation
of factors that include disease activity or pain, inactivity,
depression, obesity and poor sleep [36]. Due to the per-
vasive effect of RA on patient outcomes and its impact
on health status and QoL, it was deemed crucial to in-
corporate a component of ‘psychosocial support’ in the
intervention. ‘Psychosocial support’ aimed to address the
challenging domains of coping with RA including medi-
cation adherence by influencing behaviour change.
Against this background, the key reasons for undertaking
the TITRATE trial are:
 Remission is the most appropriate target in RA [37]
 Intensive management regimens using DMARD
combinations, steroids and sometimes biologics,
together with a ‘treatment support’ programme of
effective non-drug interventions and psychosocial
support for coping with the various domains of RA
are most likely to achieve remission [38, 39]
 The most important group of patients in which to
investigate whether intensive management achieves
remission are those with ‘intermediate disease
activity’; these patients currently continue to have
persisting disease activity and as a consequence they
develop progressive disability [40]
The TITRATE trial is designed to show whether pa-
tients with intermediate disease activity benefit from
such intensive management.
As a consequence of these considerations the trial will
enrol patients with intermediately active RA defined by
their DAS28 scores. The intervention will be intensive
management with DMARDs and biologics given in a
supportive manner agreed with individual patients. The
control group will receive standard care following exist-
ing national guidance. The
primary outcome will be remission at 12 months
assessed using DAS28. The hypothesis is that intensive
management will increase the number of patients in
DAS28 remission at 12 months compared with SC.
Methods
Aim and hypothesis
TITRATE is a robust pragmatic clinical trial to improve
outcomes for RA patients with intermediate disease activ-
ity by using an Intensive Management Programme. The
trial will test the hypothesis that patients with established
RA, who currently have intermediate disease activity
(defined as DAS28-ESR of 3.2–5.1 with at least three
active joints) and are currently receiving at least one
DMARD, are more likely to achieve remission at
12 months if they receive intensive management than if
they continue to have SC.
The primary objective is to improve outcomes defined
through achieving remission at 12 months for RA patients
with intermediate disease activity using intensive
management.
The secondary objectives are as follows:
Clinical outcomes
 To assess disability with the Health Assessment
Questionnaire (HAQ)
 To determine the relative effect on quality of life
(QoL)
 To assess acceptability of intensive management to
RA patients with intermediate disease activity
 To assess the risks of adverse events from intensive
management
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Economic outcome
 To determine the cost-effectiveness of intensive
management
Design
The TITRATE trial is a 12-month, pragmatic, rando-
mised, open-label, two-arm, parallel-group, multicentre
trial undertaken at 35–40 specialist rheumatology clinics
across England. The trial was designed by key stake-
holders including rheumatologists with experience of
treating RA, specialist nurses, GPs with a special interest
in musculoskeletal disease, methodologists and two ser-
vice users, who were patients with personal experiences
of living with RA. The study design outlining the inten-
sive management approach and standard treatment is
shown in Fig. 1. A Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) Checklist is
provided as Additional file 1, and a flow diagram is in-
cluded as Fig. 2.
The trial assesses a treatment strategy rather than
any particular drug therapy and all treatments will be
used within their current marketing authorisation.
Consequently, the Medicines and Healthcare Products
Regulatory Agency decided that the trial did not meet
their criteria for a Clinical Trial of an Investigational
Medicinal Product (CTIMP) and that TITRATE was a
non-CTIMP trial.
Ethical approval for this trial was obtained from the
London – West London and GTAC National Research
Ethics Service (NRES) Committee.
Setting
The trial will be undertaken within routine rheumatol-
ogy outpatient clinics in approximately 40 hospitals in




Fig. 1 Study design: outline of intensive management approach and standard treatment arms
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Target population
The target population will be patients attending specialist
rheumatology clinics who meet the most recent classifica-
tion criteria for RA (American College of Rheumatology
2010 criteria); have established RA; currently have inter-
mediate disease activity (DAS28-ESR of 3.2–5.1 and at
least three active joints) and are receiving at least one con-
ventional DMARD. Participants will need to meet the fol-
lowing eligibility criteria:
Inclusion criteria
1. Men and women aged over 18 years
2. Diagnosis of RA (by American College of
Rheumatology (ACR), 2010 criteria) [41]
3. Have received at least one DMARD for at least
6 months, and currently receiving at least one DMARD
4. Have intermediate disease activity, defined by: (a)
DAS28-ESR of 3.2–5.1; (b) at least three active joints
(defined as swollen and/or tender) on 66/68 joint
count, to include at least one swollen joint
5. Willing and able to follow an Intensive Management
Programme
6. Able and willing to give informed consent
Exclusion criteria
1. Major co-morbidities making intensive treatment
inadvisable (e.g. heart failure)
2. Previously failed multiple DMARDs (at least five
treatments) or having received biologics
3. Irreversible disability from extensive joint damage
(e.g. replacement of three or more major joints)
Fig. 2 Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) Schedule of enrolment, interventions and assessments
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4. Women who are pregnant, breast-feeding or at risk
of conceiving
5. Current or recent (within the 12 weeks prior to
randomisation) participation in another
interventional trial
6. Currently in an early RA pathway, which is a 12-month
treatment programme for patients with early inflamma-
tory arthritis, in which patients receive intensive treat-
ment with DMARD combinations and steroids and are
reviewed monthly by specialist nurses or equivalent
members of the rheumatology team; this is one of the
current NHS Best Practice Tariffs [42]
Interventions
Standard care
In the standard care arm, clinicians will follow their local
pathways for managing RA patients with intermediate
disease activity. These will be based on national guid-
ance from NICE. The key components of the standard
care algorithm comprise:
 Maintaining suppressive treatment with DMARDs
and steroids
 Seeing patients at least once each year in line with
local pathways of care
 Arranging urgent specialist reviews using routine
approaches if there be a clinical need
Intensive management
In the intensive management arm, patients will be seen
monthly by trained health practitioners, who will often,
but not always, be a nurse identified by the principal in-
vestigator as being competent to provide the interven-
tion, who will:
 Assess their RA and current general functioning
 Evaluate their drug treatment
 Modify the drug treatment according to a decision
tool (or algorithm) in line with a ‘shared treatment
plan’ formulated during the first visit. Shared
treatment plans will involve agreements with
patients about drugs, dosages and therapeutic
sequences. Templates for potential shared treatment
plans were developed with patients in advance of the
trial as part of a preparatory study within the
TITRATE programme
 Provide supportive care according to the principles,
knowledge and skills acquired in the training course
which are underpinned by Motivational Interviewing
techniques and are included in the Treatment
Support Manual
The Intensive Management Programme will address
the following:
1. Provide information: there will be a handbook for
patients [43] which will describe in detail the various
aspects of intensive treatment as well as information
on psychoeducation such as details of medication
side effects, ways of coping with the physical and
emotional symptoms and the impact of RA on
everyday life, contact details for support groups, and
disability information
2. Optimise DMARDs/biologics: drug treatment will be
modified following a treatment algorithm, which will
recommend treatment options based on previous
treatment, present treatment, contraindications, the
patient’s preferences and clinical assessments. The
premise of the treatment algorithm is that, if the
patient’s disease is still active, whatever the current
treatment strategy, the recommended strategy will
always reflect potential intensification of treatment.
All medication given to patients in the intensive
management group will be in line with national
guidance from NICE or the national specialist
society (British Society for Rheumatology) [44] the
only differences being that patients will be reviewed
more frequently than they would be under standard
care and if their disease is not fully controlled may
be given biological therapies in line with British
Society for Rheumatology recommendations. Local
safety screening for tuberculosis and other infections
will be performed according to local guidelines for
patients in the intensive management arm prior to
starting biologics (if needed) in line with British
Society for Rheumatology guidance
3. Give steroids: patients will receive intra-muscularly
administered steroids (depomedrone or equivalent) if
their arthritis is not fully controlled up to a maximum
of 600 mg depomedrone (or equivalent) over the
12-month period. The dose of steroids given will range
from 40 to 120 mg depending on specific clinical
circumstances
4. Provide treatment support: along with treating
patients more intensively with medication, the
trained rheumatology practitioner will also provide
patients in this group with supportive care. Patients
will be educated and supported in a number of
domains commonly affected by RA, with a particular
focus on: pain and fatigue management; physical
activity; medication adherence, sleep and low mood/
anxiety. Patients will also have a handbook,
co-developed with patients and national charities,
which includes psychoeducation about their
condition, treatment options and ways of coping
with the physical and emotional symptoms
All specialist rheumatology practitioners involved in de-
livering the intensive management intervention will be
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trained according to a manualised training programme to
ensure that the intervention provided is standardised
across sites and participants. The training involves a 2-day
course, with day 1 focussing solely on motivational inter-
viewing techniques; specifically, open-ended questions, af-
firmations, reflections/reflective listening and summaries
and the treatment algorithm for intensive management.
The second day focusses on psychoeducation regarding
various aspects of RA including preparation for behaviour
change, goal-setting, diary keeping, self-monitoring, devel-
opment of a shared treatment plan, standardisation of the
DAS28 scoring process, explanation of the process of re-
cording the sessions and the supervision that will be avail-
able to practitioners [26]. To measure adherence to the
intensive management intervention across sites, monthly
sessions will be audiotaped and a randomly selected
subset of these rated by a team of three independent
assessors.
Assessments
Assessments will be carried out by a member of the re-
search team at each participating centre. Following
consent and confirmation of eligibility, all patients will
complete an initial baseline assessment. This will be
followed by a midpoint and final assessment at 6 and
12 months from baseline, respectively. See Table 1 for a
summary of the milestone research assessments.
Primary outcome measure
The primary outcome will be the number of patients in
each treatment arm fulfilling the definition of remission
as measured by DAS28-ESR (remission defined as
DAS28-ESR < 2.6) [45, 46] at 12 months.
Secondary outcome measures
These will assess the following outcomes at 6 and/or
12 months:
 Alternative assessments of remission: remission
measured by the Disease Activity Score for 28
joints-C-reactive protein score (DAS28-CRP) [46, 47]
the Simplified Disease Activity Index (SDAI)
(remission defined as SDAI ≤ 3.3) [48] at 12 months;
remission assessed by all measures at 6 months
Table 1 Summary of milestone assessments
Assessment Baseline Month 6 (midpoint) Month 12 (final) Withdrawala Extension studyb
DAS28 (ESR) and Extended Joint Count X X X X X
CRP X X X X X
Assessor global rating (VAS) X X X X X
Pain rating (VAS) X X X X X
Fatigue rating (VAS) X X X X X
RA medication X X X X X
Medical history X
Alcohol consumption X
Smoking history/status X X X X
X-rays (plain, of hands and feet) X X X
HAQ X X X X X
CSRI X X X X
EQ-5D-5 L X X X X X
PHQ-9 X
GAD-7 X
MARS X X X X
BIPQ X
BMQ X
Views of RA treatment X X X
Adverse events X X X X
DAS28-ESR will be calculated from joint count, patient global rating (VAS) and ESR during every visit; SDAI will be calculated from joint count, patient global rating
(VAS), assessor global rating (VAS) and CRP at baseline, midpoint and final assessments
aTo be completed at any time during the trial if the patient withdraws. bExtension study only
BIPQ Brief Illness Perceptions Questionnaire, BMQ Beliefs about Medicines Questionnaire, CRP C-reactive protein, CSRI Modified Client Service Receipt Inventory,
EQ-5D-5 L EuroQol 5-dimensional 5-level score, ESR erythrocyte sedimentation rate, GAD-7 Generalized Anxiety disorder-7, HAQ Health Assessment Questionnaire,
MARS Medication Adherence Rating Scale, PHQ-9 Patient Health Questionnaire-9, RA rheumatoid arthritis, SDAI Simplified Disease Activity Index, VAS Visual
Analogue Scale
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 Assessment of individual components of remission:
tender joint counts (68 joints), swollen joint counts
(66 joints), patient global assessments on 100-mm a
Visual Analogue Scale (VAS), assessor global
assessments on 100-mm VAS, C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR)
 Disability: Health Assessment Questionnaire (HAQ)
[49]
 Joint imaging (predictor of future disability): plain
X-rays of the hands and feet read by a modified
Larsen’s score [50]
 Quality of life: EuroQoL 5-dimensional 5-level score
(EQ-5D-5 L) [51], fatigue rating (VAS)
 Patient acceptability: Modified Measuring Actual
Patient-led Expectations in Rheumatoid Arthritis
(MAPLe-RA) [52], Medication Adherence Rating
Scale (MARS) [53]
 Adverse events
 Economic assessments: Modified Client Service
Receipt Inventory (CSRI) [54]
Potential predictor variables (psychosocial measures)
Baseline assessments will include evaluation of a number
of potential outcome predictors, which will be used in
exploratory analyses. These will include:
 Lifestyle factors: alcohol consumption and tobacco
smoking
 Mood and anxiety: Patient Health Questionnaire-9
(PHQ-9) [55] and Generalised Anxiety Disorder-7
(GAD-7) [56]
 Health beliefs/illness perceptions: Beliefs about
Medicines Questionnaire (BMQ) [57] and Brief
Illness Perceptions Questionnaire (BIPQ) [58]
Withdrawal of participants
Participants have the right to withdraw from the study
at any time for any reason. Patients wishing to withdraw
from the study will be asked to complete a withdrawal
assessment, which is the equivalent of a final (month-12)
assessment.
Patients in the intensive management arm who wish
to withdraw will be given the following options:
1. Withdrawal from intervention: revert to treatment as
usual and complete 6- and/or 12-month follow-up
assessments
2. Medical note review only: revert to treatment as
usual but consent to collection of data from routine
medical notes (no follow-up assessments completed)
3. Withdrawal from research: refuse any further
collection of outcome data, either through follow-up
assessments or medical note review
Patients in the standard care arm who wish to withdraw
will be given the following options:
1. Medical note review only: consent to collection of data
from routine medical notes (no follow-up assessments
completed)
2. Withdrawal from research: refuse any further
collection of outcome data, either through follow-up
assessments or medical note review
Extension study for patients in the intensive management
arm
To investigate whether disease activity and the impact of
RA on general health remain stable after a period of
12 months of intensive management, we will undertake an
exploratory study of the future outcome of patients in the
intensive management arm of the trial. After completing
12 months in the intensive management arm, patients will
return to receiving contemporary standard care treatment
following local pathways for managing RA patients with
intermediate disease activity. These patients will be invited
to complete an additional assessment 6 months after
completing the trial. This assessment will include mea-
sures of remission and a subset of patient-completed
questionnaires used in the main trial. See Table 1 for
further details.
Sample size
One of the most relevant UK trials (TICORA) compared
tight control versus standard treatment in patients with
RA for less than 5 years; it reported that 16% of patients
receiving standard care achieved DAS remission at the
end of the trial [59]. We therefore assume that with
standard care 16% of patients will have achieved DAS re-
mission at 1-year follow-up.
We will reject the null hypothesis (RA patients with
intermediate disease activity (DAS28 3.2–5.1), despite
DMARDs, will not have more remissions following
12 months of intensive management) if the difference in
remission rates at 12 months between the intensive
management arm and the standard care arm is 15% or
greater. Demonstrating such a difference with 5% signifi-
cance and 90% power requires randomising 358 patients
in total, under 1:1 allocation (i.e. 179 patients per group).
However, if we assume that 10% of patients will not pro-
vide follow-up information at the end of the study the
required total sample size increases to 398 patients (199
per arm).
Randomisation
Only when all baseline measures are complete and data
is entered will patients be randomised. Randomisation
will be at the level of the individual using block random-
isation with randomly varying block sizes, to ensure pre-
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randomisation allocation concealment, stratified by site.
Patients will be randomised to intensive management
(IM) or standard care (SC) in a ratio of 1:1. All staff in-
volved in the conduct of the trial will be unaware of the
allocation sequence. The trial will not be blinded. Patients
are an integral part of the intensive treatment algorithm
and there is no possible way to blind such a trial.
Data analysis
Analysis will be on an intention-to-treat (ITT) basis to
reflect the randomisation process. We will also carry out
two additional analyses populations: a complete case
population: these will be observations that subjects
complete the trial without missing data or violation of
the protocol and, therefore, referred to as ‘complete case
analysis’. A per-protocol population: these will be obser-
vations that will be excluded from these analyses if pa-
tients are found to deviate from the protocol and
referred to as ‘per-protocol analysis’.
Baseline characteristics will be summarised by rando-
mised group. The Multiple Imputations (MI) method
will be used to impute missing primary or secondary
outcomes. The robustness of the analyses performed to
the missing at random assumption under MI model will
be assessed by Linear Increment method of Diggle et al.
[60] to handle the missingness.
A logistic regression analysis will be used to analyse
the primary outcome – remission at 12 months. For sec-
ondary analyses that involve longitudinal measurements,
generalised estimating equations (GEE) and/or mixed
models will be used to estimate the effect of treatment,
including baseline value as a covariate. Working correl-
ation matrices will be unstructured, which is not unduly
restrictive given that measurements will be taken at
three time points. Valid/robust estimates of the precision
of effects will be obtained through use of the informa-
tion sandwich estimator for GEE analyses.
Treatment, and the demographic factors (age,
ethnicity, gender, disease duration) as well as the de-
sign factor (region) will be included as explanatory
variables in the multivariate analysis. The design fac-
tor will also be accounted for in the univariate model.
The estimates for primary outcome will be presented
as odds ratios (OR) with 95% confidence intervals for
the effect of intensive management. Statistical signifi-
cance will be determined at the 5% level using a two-
sided test throughout.
Serious adverse event and adverse rates in the two
arms will be compared using comparisons of two inde-
pendent proportions.
Analysis of the exploratory extension study will use the
final assessment in the TITRATE trial and the new 6-month
follow-up data to compare the proportion of patients in
remission at 12 and 18 months. Simple descriptive analysis
will be used to determine the numbers of patients in remis-
sion and changes in the key clinical and functional
outcomes.
A full statistical analysis plan was developed prior to
the start of the trial.
Cost utility analysis
A cost-utility analysis will be undertaken to estimate the
incremental cost per quality-adjusted life year (QALY) of
intensive management compared to standard care in RA
patients with intermediate disease activity, alongside the
clinical trial.
The cost-utility analysis will be conducted in line with
the NICE Guide to the Methods of Technology Ap-
praisal (2013) [61]. In particular, an NHS and Personal
Social Services (PSS) perspective will be taken for costs,
and health benefits will be quantified using QALYs.
The primary analysis will be an economic evaluation
alongside the clinical trial, and will use the 1-year follow-
up period of the trial to estimate expected 1-year costs
and QALYs for the intervention and control groups.
QALYs will be estimated using the EuroQol (5-level) ques-
tionnaire reported at baseline, 6 months and 12 months.
The EuroQol will be valued using population tariff values
to estimate EQ-5D-5 L scores. Although these are not yet
published, they are expected to be available during 2013.
QALYs will be estimated using the trapezium rule to
calculate the area under the curve.
NHS resource use will be measured for each partici-
pant between baseline and final follow-up. This will in-
clude all medication costs, visits to health services and
any social care and community support. Medical costs
will be taken from the trial medication records, and
other NHS and resources used will be self-reported
using the widely used and validated Client Service Re-
ceipt Inventory (CSRI) questionnaire [54]. Unnecessary
questions in the CSRI will be removed to reduce the
burden for patients; however, questions relating to per-
sonal costs incurred and time off work will be retained
for a sensitivity analysis.
The estimate of cost-effectiveness will be reported as
the incremental cost-effectiveness ratio (ICER). Patient
variation in resource use and effectiveness will be cap-
tured by confidence intervals of the cost and outcome
estimates separately. Due to the ratio property of the
ICER, confidence intervals are less reliable and, there-
fore, bootstrapped estimates of the ICERs will be sam-
pled to allow the probability of the intervention being
cost-effective to be determined. This estimate of uncer-
tainty will be reported using cost-effectiveness accept-
ability curves (CEACs), which report the probability that
the intervention is cost-effective for any given level of
willingness to pay.
Martin et al. Trials  (2017) 18:591 Page 9 of 12
A secondary analysis will be undertaken with a wider
societal perspective. Personal costs and time off work
will be included, as reported by patients using the CSRI
questionnaire. Time off work will be valued as product-
ivity losses using the Human Capital Method.
A potential tertiary analysis will include an extrapolation
of the costs and benefits of the intervention, to allow a
life-time estimate of expected costs and QALYs. Time to
loss of efficacy of the intervention will be determined by a
survival analysis of the within-trial data. This will be in-
cluded in an established decision analytic model (The
Sheffield RA Model) [62]. The model will determine the
future treatment pathway for the patient populations once
a switch from intensive DMARD therapy is estimated, in-
cluding biologics if patients progress to severe RA.
Discussion
TITRATE is intended to establish the clinical and cost-
effectiveness of intensive treatment strategies in estab-
lished RA patients with intermediate disease activity.
Three complex problems have come to light during
our ongoing research into RA patients with intermediate
disease linked to the TITRATE trial. The first of these is
the potential heterogeneity of these patients. In some
there is evidence of persisting inflammatory arthritis,
with several swollen joints and an elevated ESR. In
others the DAS28 mainly reflects high tender joint
counts and high patient global assessments; these latter
patients may have a pattern of fibromyalgic RA and they
may not respond greatly to DMARDs [63]. There is in-
sufficient information about whether or not fibromyalgic
RA represents a distinct group of patients or whether it
reflects higher pain scores in a minority of patients who
otherwise have a similar clinical phenotype. More infor-
mation is needed to resolve this question.
The second problem is whether remission is the opti-
mal target, or if low disease activity is adequate. Al-
though disability is minimised and QoL is maximised
when patients achieve remission, more patients will
achieve low disease activity and remission than remis-
sion alone. For this reason, it might be preferable to have
a broader target which is achieved more often than the
narrower target of remission. Secondary analyses will
examine both remission and low disease activity states.
However, further research is needed to identify the opti-
mal treatment target, particularly in patients with estab-
lished RA in whom some joint damage and disability
may already have become irreversible.
The third potential problem is the marked variability in
the training and experience of rheumatology nurses in
England. Some rheumatology nurses are very experienced
with high skill levels and knowledge. However, many have
relatively little experience in the specialty. The extent of
this variation reflects the absence of any agreed accredited
national training programme for nurses. One complexity
in assessing the impact of training is the relative propensity
of healthcare professionals to learn and implement a new
approach, such as the intensive management intervention
we have described. Whilst experienced nurses may have
the greatest knowledge and skills they may also be the least
likely to adopt new approaches. It is likely that several
nurse/practitioner-related factors are implicated when ap-
plying innovative management approaches to long-term
disorders like RA.
Many RA patients have intermediate disease activity, so
we anticipate that the results of the TITRATE trial will in-
form the NHS on how best to manage these patients and
the benefits of delivering a more intensive management
approach provided such an approach is found to be both
effective and cost-effective.
Several other factors may influence interpretation of the
trial results. One issue is that intensive management might
have positive impacts on some secondary outcomes alone;
for example, improving QoL without increasing remis-
sions. As a number of secondary outcomes are being mea-
sured caution will be used in interpretation such findings.
Another issue is that patients or clinicians may be reluc-
tant to sufficiently increase therapy in the intensive man-
agement group or may give more intensive treatment to
the usual care group. Finally, there is the potential impact
of evaluating different response thresholds; defining re-
mission using DAS28 involves dichotomising patients
based on where they fall on a continuous line and it is
possible that views will change on the optimal threshold
for this division. Caution will be needed in interpreting
the assessment of different thresholds in the final analysis.
Trial status
Participants are currently being recruited. The first patient
was enrolled in June 2014.
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